TABLE 4.
Univariate and multivariate analyses of potential predictive factors of death hazard.
| a Univariate analyses HR (95% CI) | p‐value | a Multivariate analyses HR (95% CI) | p‐value | b Univariate analyses HR (95% CI) | p‐value | b Multivariate analyses HR (95% CI) | p‐value | |
|---|---|---|---|---|---|---|---|---|
| Male | 1.40 (0.86, 2.30) | 0.1761 | 2.41 (0.84, 6.95) | 0.1034 | ||||
| Age >60 years | 1.23 (0.81, 1.86) | 0.3417 | 0.88 (0.48, 1.62) | 0.6838 | ||||
| Smoking | 1.62 (1.05, 2.50) | 0.0287 | 1.38 (0.84, 2.27) | 0.2084 | 1.55 (0.71, 3.40) | 0.2716 | ||
| BMI <18.5 | 0.97 (0.54, 1.75) | 0.9151 | 0.93 (0.32, 2.72) | 0.8911 | ||||
| ECOG‐PS 2‐3 | 1.03 (0.50, 2.13) | 0.9442 | 0.95 (0.28, 3.25) | 0.9293 | ||||
| Other histological type | 0.82 (0.33, 2.02) | 0.6629 | 0.44 (0.11, 1.85) | 0.2647 | ||||
| Stage IV | 1.00 (0.56, 1.80) | 0.9971 | 1.84 (0.84, 4.01) | 0.1267 | ||||
| Brain metastases | 0.93 (0.53, 1.65) | 0.8035 | 1.53 (0.72, 3.21) | 0.2660 | ||||
| Contralateral lung metastases | 1.26 (0.82, 1.94) | 0.2967 | 1.13 (0.57, 2.27) | 0.7243 | ||||
| Pleural metastases | 1.02 (0.66, 1.58) | 0.9215 | 1.12 (0.59, 2.13) | 0.7318 | ||||
| Pericardial metastases | 0.77 (0.28, 2.10) | 0.6079 | 0.00 (0.00, Inf) | 0.9976 | ||||
| Liver metastases | 1.70 (0.98, 2.94) | 0.0587 | 1.22 (0.65, 2.29) | 0.5260 | 1.83 (0.84, 3.99) | 0.1308 | ||
| Adrenal metastases | 1.76 (1.04, 3.00) | 0.0357 | 1.14 (0.62, 2.11) | 0.6658 | 2.30 (1.12, 4.72) | 0.0232 | 5.43 (1.71, 17.23) | 0.0040 |
| Bone metastases | 1.20 (0.79, 1.83) | 0.3993 | 1.79 (0.95, 3.38) | 0.0728 | 1.16 (0.35, 3.85) | 0.8065 | ||
| Number of metastatic sites ≥2 | 1.83 (1.20, 2.79) | 0.0047 | 1.92 (1.17, 3.14) | 0.0096 | 1.98 (1.08, 3.65) | 0.0282 | 1.58 (0.43, 5.83) | 0.4935 |
| Taxanes ± platinum | 1.0 | 1.0 | ||||||
| Pemetrexed ± platinum | 1.05 (0.56, 1.97) | 0.8701 | 0.80 (0.27, 2.40) | 0.6971 | ||||
| Chemotherapy + antiangiogenesis/immunotherapies | 1.04 (0.47, 2.29) | 0.9208 | 0.68 (0.20, 2.27) | 0.5302 | ||||
| KRAS WT | 1.0 | 1.0 | ||||||
| KRAS mutation | 2.36 (1.55, 3.61) | <0.0001 | 2.39 (1.53, 3.73) | 0.0001 | ||||
| KRAS G12C | 1.76 (0.86, 3.60) | 0.1225 | 1.78 (0.83, 3.78) | 0.1361 | 1.0 | 1.0 | ||
| KRAS non‐G12C | 3.45 (1.98, 6.00) | <0.0001 | 4.10 (2.32, 7.25) | <0.0001 | 2.15 (0.93, 5.00) | 0.0738 | 2.27 (0.82, 6.33) | 0.1160 |
Note: Independent variables with p < 0.10 in the univariate analyses were included in the Cox proportional hazards model. p values < 0.05 were highlighted in bold.
Abbreviations: BMI, body mass index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; WT, wild‐type.
a
Univariate and multivariate analysis for death hazard in all patients after first‐line treatment.
b
Univariate and multivariate analysis for death hazard in KRAS‐mutated patients after first‐line treatment.